IL-34 is a Treg-specific cytokine and mediates transplant tolerance

Journal of Clinical Investigation

Volumn 125, Issue 10, 2015, Pages 3952-3964

  Bézie, Séverine ^a   Picarda, Elodie ^a   Ossart, Jason ^a   Tesson, Laurent ^a   Usal, Claire ^a   Renaudin, Karine ^b   Anegon, Ignacio ^a   Guillonneau, Carole ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; CD45 ANTIGEN; CD45RC ANTIGEN; CYTOKINE; INTERLEUKIN 34; RAPAMYCIN; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 34; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR RECEPTOR; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; FOXP3 PROTEIN, RAT; HYBRID PROTEIN; INTERLEUKIN DERIVATIVE; INTERLEUKIN-34, HUMAN; INTERLEUKIN-34, RAT; MESSENGER RNA;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIAC GRAFT REJECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL MIGRATION; CONTROLLED STUDY; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IN VITRO STUDY; MACROPHAGE; MALE; MEDIATOR; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RAT; REGULATORY T LYMPHOCYTE; RODENT; ADOPTIVE TRANSFER; ALLOGRAFT; ANIMAL; BIOSYNTHESIS; DEPENDOPARVOVIRUS; DRUG EFFECTS; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; LEWIS RAT; LYMPHOCYTE ACTIVATION; PHYSIOLOGY; T LYMPHOCYTE SUBPOPULATION; TISSUE MICROARRAY; TRANSPLANTATION TOLERANCE;

ADOPTIVE TRANSFER; ALLOGRAFTS; ANIMALS; ANTIGENS, CD45; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DEPENDOVIRUS; FORKHEAD TRANSCRIPTION FACTORS; GENETIC VECTORS; HEART TRANSPLANTATION; HEK293 CELLS; HUMANS; INTERLEUKINS; LYMPHOCYTE ACTIVATION; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MALE; RATS; RATS, INBRED LEW; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TISSUE ARRAY ANALYSIS; TRANSDUCTION, GENETIC; TRANSPLANTATION TOLERANCE;

EID: 84943279887     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI81227     Document Type: Article

References (53)

1. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349(24):2326-2333.
2. Srinivas TR, Kaplan B. Transplantation in 2011: New agents, new ideas and new hope. Nat Rev Nephrol. 2012;8(2):74-75.
3. Londono MC, Danger R, Giral M, Soulillou JP, Sanchez-Fueyo A, Brouard S. A need for biomarkers of operational tolerance in liver and kidney transplantation. Am J Transplant. 2012;12(6):1370-1377.
4. Wood KJ, Bushell A, Hester J. Regulatory immune cells in transplantation. Nat Rev Immunol. 2012;12(6):417-430.
5. Niederkorn JY. Emerging concepts in CD8(+) T regulatory cells. Curr Opin Immunol. 2008;20(3):327-331.
6. Picarda E, Anegon I, Guillonneau C. T-cell receptor specificity of CD8(+) Tregs in allotransplantation. Immunotherapy. 2011;3(4 suppl):35-37.
7. Guillonneau C, Picarda E, Anegon I. CD8+ regulatory T cells in solid organ transplantation. Curr Opin Organ Transplant. 2010;15(6):751-756.
8. Menoret S, Guillonneau C, Bezie S, Caron L, Anegon I, Li XL. Phenotypic and functional characterization of CD8(+) T regulatory cells. Methods Mol Biol. 2011;677:63-83.
9. Wei S, et al. Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. J Leukoc Biol. 2010;88(3):495-505.
10. Nandi S, et al. Receptor-type protein-tyrosine phosphatase zeta is a functional receptor for interleukin-34. J Biol Chem. 2013;288(30):21972-21986.
11. Chihara T, et al. IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation. Cell Death Differ. 2010;17(12):1917-1927.
12. Wang Y, et al. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol. 2012;13(8):753-760.
13. Chemel M, et al. Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients. Ann Rheum Dis. 2012;71(1):150-154.
14. Baud'huin M, et al. Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis. J Pathol. 2010;221(1):77-86.
15. Spickett GP, Brandon MR, Mason DW, Williams AF, Woollett GR. MRC OX-22, a monoclonal antibody that labels a new subset of T lymphocytes and reacts with the high molecular weight form of the leukocyte-common antigen. J Exp Med. 1983;158(3):795-810.
16. Xystrakis E, Bernard I, Dejean AS, Alsaati T, Druet P, Saoudi A. Alloreactive CD4 T lymphocytes responsible for acute and chronic graftversus-host disease are contained within the CD45RChigh but not the CD45RClow subset. Eur J Immunol. 2004;34(2):408-417.
17. Xystrakis E, et al. Identification of a novel natural regulatory CD8 T-cell subset and analysis of its mechanism of regulation. Blood. 2004;104(10):3294-3301.
18. Guillonneau C, et al. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-γ, and indoleamine 2,3-dioxygenase. J Clin Invest. 2007;117(4):1096-1106.
19. Powrie F, Mason D. OX-22high CD4+ T cells induce wasting disease with multiple organ pathology: prevention by the OX-22low subset. J Exp Med. 1990;172(6):1701-1708.
20. Ordonez L, Bernard I, L'Faqihi-Olive FE, Tervaert JW, Damoiseaux J, Saoudi A. CD45RC isoform expression identifies functionally distinct T cell subsets differentially distributed between healthy individuals and AAV patients. PLoS One. 2009;4(4):e5287.
21. Li XL, et al. Mechanism and localization of CD8 regulatory T cells in a heart transplant model of tolerance. J Immunol. 2010;185(2):823-833.
22. Bezie S, et al. Fibrinogen-like protein 2/fibroleukin induces long-term allograft survival in a rat model through regulatory B cells. PLoS One. 2015;10(3):e0119686.
23. Picarda E, et al. MHC-derived allopeptide activates TCR-biased CD8+ Tregs and suppresses organ rejection. J Clin Invest. 2014;124(6):2497-2512.
24. Lin H, et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science. 2008;320(5877):807-811.
25. Garceau V, et al. Pivotal Advance: Avian colonystimulating factor 1 (CS9F-1), interleukin-34 (IL-34), and CSF-1 receptor genes and gene products. J Leukoc Biol. 2010;87(5):753-764.
26. Fancke B, Suter M, Hochrein H, O'Keeffe M. M-CSF: a novel plasmacytoid and conventional dendritic cell poietin. Blood. 2008;111(1):150-159.
27. MacDonald KP, et al. The colony-stimulating factor 1 receptor is expressed on dendritic cells during differentiation and regulates their expansion. J Immunol. 2005;175(3):1399-1405.
28. Gilmore GL, Shadduck RK. Inhibition of day-12 spleen colony-forming units by a monoclonal antibody to the murine macrophage/monocyte colony-stimulating factor receptor. Blood. 1995;85(10):2731-2734.
29. Ordonez L, et al. A higher risk of acute rejection of human kidney allografts can be predicted from the level of CD45RC expressed by the recipients' CD8 T cells. PLoS One. 2013;8(7):e69791.
30. Toromanoff A, et al. Safety and efficacy of regional intravenous (r.i.) versus intramuscular (i.m.) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle. Mol Ther. 2008;16(7):1291-1299.
31. Le Texier L, et al. Immunoregulatory function of IL-27 and TGF-beta1 in cardiac allograft transplantation. Transplantation. 2012;94(3):226-233.
32. Foucher ED, et al. IL-34 induces the differentiation of human monocytes into immunosuppressive macrophages. antagonistic effects of GM-CSF and IFNγ. PLoS One. 2013;8(2):e56045.
33. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014;6:13.
34. Murray PJ, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14-20.
35. Cobbold SP, et al. Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci U S A. 2009;106(29):12055-12060.
36. Riquelme P, et al. IFN-gamma-induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients. Mol Ther. 2013;21(2):409-422.
37. Campbell IK, Rich MJ, Bischof RJ, Hamilton JA. The colony-stimulating factors and collageninduced arthritis: exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF. J Leukoc Biol. 2000;68(1):144-150.
38. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008;8(7):533-544.
39. Eda H, Zhang J, Keith RH, Michener M, Beidler DR, Monahan JB. Macrophage-colony stimulating factor and interleukin-34 induce chemokines in human whole blood. Cytokine. 2010;52(3):215-220.
40. Doyle AG, Halliday WJ, Barnett CJ, Dunn TL, Hume DA. Effect of recombinant human macrophage colony-stimulating factor 1 on immunopathology of experimental brucellosis in mice. Infect Immun. 1992;60(4):1465-1472.
41. Sakurai T, Wakimoto N, Yamada M, Shimamura S, Motoyoshi K. Effect of macrophage colonystimulating factor (M-CSF) on mouse immune responses in vivo. Immunopharmacol Immunotoxicol. 1998;20(1):79-102.
42. Sakurai T, Yamada M, Simamura S, Motoyoshi K. Recombinant human macrophage-colony stimulating factor suppresses the mouse mixed lymphocyte reaction. Cell Immunol. 1996;171(1):87-94.
43. Duluc D, et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood. 2007;110(13):4319-4330.
44. Hashimoto D, et al. Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. J Exp Med. 2011;208(5):1069-1082.
45. Menoret S, et al. Characterization of immunoglobulin heavy chain knockout rats. Eur J Immunol. 2010;40(10):2932-2941.
46. Larcher T, et al. Characterization of dystrophin deficient rats: a new model for Duchenne muscular dystrophy. PLoS One. 2014;9(10):e110371.
47. Chen Z, Buki K, Vaaraniemi J, Gu G, Vaananen HK. The critical role of IL-34 in osteoclastogenesis. PLoS One. 2011;6(4):e18689.
48. Tzachanis D, Berezovskaya A, Nadler LM, Boussiotis VA. Blockade of B7/CD28 in mixed lymphocyte reaction cultures results in the generation of alternatively activated macrophages, which suppress T-cell responses. Blood. 2002;99(4):1465-1473.
49. Liu G, Duan K, Ma H, Niu Z, Peng J, Zhao Y. An instructive role of donor macrophages in mixed chimeras in the induction of recipient CD4(+)Foxp3(+) Treg cells. Immunol Cell Biol. 2011;89(8):827-835.
50. Holt PG, Schon-Hegrad MA, Oliver J. MHC class II antigen-bearing dendritic cells in pulmonary tissues of the rat. Regulation of antigen presentation activity by endogenous macrophage populations. J Exp Med. 1988;167(2):262-274.
51. Jose MD, Le Meur Y, Atkins RC, Chadban SJ. Blockade of macrophage colony-stimulating factor reduces macrophage proliferation and accumulation in renal allograft rejection. Am J Transplant. 2003;3(3):294-300.
52. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods. 1994;174(1-2):83-93.
53. Guillonneau C, et al. The role of TNF-related activation-induced cytokine-receptor activating NF-κB interaction in acute allograft rejection and CD40L-independent chronic allograft rejection. J Immunol. 2004;172(3):1619-1629.